The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
A Randomized Controlled Clinical Trial of the Serotonin Type 3 Receptor Antagonist Alosetron in Women With Diarrhea-Predominant Irritable Bowel Syndrome
Abstract
BACKGROUND: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder seen in primary care practice. The symptoms of IBS, including abdominal pain, discomfort, and abnormal bowel function, may be modulated by activity of the serotonin type 3 receptor (5-HT(3)). The efficacy and tolerability of the 5-HT(3) receptor antagonist alosetron hydrochloride in nonconstipated female patients with IBS were evaluated in a double-blind, randomized, placebo-controlled trial. METHODS: Patients received either 1 mg of alosetron hydrochloride (n = 309) or placebo (n = 317) twice daily for 12 weeks, followed by a 4-week posttreatment period. Adequate relief of IBS pain and discomfort was the primary end point. Secondary end points included improvements in urgency, stool frequency, stool consistency, incomplete evacuation, and bloating. RESULTS: Seventy-one percent of patients were classified as having diarrhea-predominant IBS. Forty-three percent of alosetron-treated patients with diarrhea-predominant IBS reported adequate relief for all 3 months compared with 26% of placebo-treated patients (P<.001; percentage point difference = 17; 95% confidence interval, 8.0-25.4). Improvement with alosetron compared with placebo was observed by the end of the fourth week of treatment and persisted throughout the remainder of treatment. Alosetron significantly decreased urgency and stool frequency and caused firmer stools within 1 week of starting treatment. Effects were sustained throughout treatment and symptoms returned following treatment cessation. No significant improvement in the percentage of days with sense of incomplete evacuation or bloating was observed compared with placebo during the first month of treatment. Constipation was the most commonly reported adverse event. CONCLUSION: Alosetron hydrochloride, 1 mg twice daily for 12 weeks, is effective in relieving pain and some bowel-related symptoms in diarrhea-predominant female patients with IBS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Berkley, K. J. (1997) · Behavioral and Brain Sciences · doi:10.1017/s0140525x97221485 · Cited by 1,125
Patrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018831127942 · Cited by 761
Design of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.010 · Cited by 550
Non-colonic features of irritable bowel syndrome.
Whorwell, P. J., McCallum, M., Creed, F. H., & Roberts, C. T. (1986) · Gut · doi:10.1136/gut.27.1.37 · Cited by 473
Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
Delvaux, M., Louvel, D., Mamet, J. ‐., Campos‐Oriola, R., & Frexinos, J. (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00375.x · Cited by 236
Houghton, Foster, & Whorwell (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00762.x · Cited by 132
Cited by
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0084-x · Cited by 388
Self-citationDesign of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Whitehead, W. E., Chey, W. D., Matsueda, K., Shaw, M., Talley, N. J., & Veldhuyzen van Zanten, S. J. O. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.058 · Cited by 286
Self-citationThe placebo effect in irritable bowel syndrome trials: a meta‐analysis1
Patel, S. M., Stason, W. B., Legedza, A., Ock, S. M., Kaptchuk, T. J., Conboy, L., Canenguez, K., Park, J. K., Kelly, E., Jacobson, E., et al. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00650.x · Cited by 285
Ford, A. C., Brandt, L. J., Young, C., Chey, W. D., Foxx-Orenstein, A. E., & Moayyedi, P. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.223 · Cited by 261
Self-citationAn Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225
Self-citationEfficacy of alosetron in irritable bowel syndrome: a meta‐analysis of randomized controlled trials
Cremonini, F., Delgado‐Aros, S., & Camilleri, M. (2003) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2003.00389.x · Cited by 219
Self-citationBlack, C. J., Burr, N. E., Camilleri, M., Earnest, D. L., Quigley, E. M., Moayyedi, P., Houghton, L. A., & Ford, A. C. (2020) · Gut · doi:10.1136/gutjnl-2018-318160 · Cited by 191
Self-citationLembo, A., Sultan, S., Chang, L., Heidelbaugh, J. J., Smalley, W., & Verne, G. N. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.04.017 · Cited by 192
Chang, L., Chey, W. D., Harris, L., Olden, K., Surawicz, C., & Schoenfeld, P. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00459.x · Cited by 181
Self-citationSerotonin and Its Role in Colonic Function and in Gastrointestinal Disorders
Costedio, M. M., Hyman, N., & Mawe, G. M. (2007) · Diseases of the Colon & Rectum · doi:10.1007/s10350-006-0763-3 · Cited by 170
Pimentel, M., Chatterjee, S., Chow, E. J., Park, S., & Kong, Y. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9104-6 · Cited by 160
Lindfors, P., Unge, P., Arvidsson, P., Nyhlin, H., Björnsson, E., Abrahamsson, H., & Simrén, M. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.340 · Cited by 138
Occurrence of Colon Ischemia in Relation to Irritable Bowel Syndrome
Cole, J. A., Cook, S. F., Sands, B. E., Ajene, A. N., Miller, D. P., & Walker, A. M. (2004) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04097.x · Cited by 121
Defining the predictors of the placebo response in irritable bowel syndrome
Pitz, M., Cheang, M., & Bernstein, C. N. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00626-3 · Cited by 111
Pharmacologic and Complementary and Alternative Medicine Therapies for Irritable Bowel Syndrome
Chey, W. D., Maneerattaporn, M., & Saad, R. (2011) · Gut and Liver · doi:10.5009/gnl.2011.5.3.253 · Cited by 89
Self-citationSafety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea
Cash, B. D., Lacy, B. E., Schoenfeld, P. S., Dove, L. S., & Covington, P. S. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.542 · Cited by 88
Lackner, J. M., Gudleski, G. D., Keefer, L., Krasner, S. S., Powell, C., & Katz, L. A. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.02.007 · Cited by 76
Schmulson, M., & Chang, L. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04637.x · Cited by 70
Pimentel, M., Kong, Y., & Park, S. (2004) · Digestive Diseases and Sciences · doi:10.1023/b:ddas.0000011607.24171.c0 · Cited by 68
Spiegel, B. M. R. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.02.030 · Cited by 67
Whitehead, W. E., Palsson, O. S., Levy, R. L., Feld, A. D., VonKorff, M., & Turner, M. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00535.x · Cited by 64
Brenner, D. M., & Sayuk, G. S. (2020) · Advances in Therapy · doi:10.1007/s12325-019-01116-z · Cited by 55
Evolution of Clinical Trials for Irritable Bowel Syndrome: Issues in End Points and Study Design
Trentacosti, A. M., He, R., Burke, L. B., Griebel, D., & Kennedy, D. L. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.12 · Cited by 42
Plasse, T. F., Barton, G., Davidson, E., Abramson, D., Kalfus, I., Fathi, R., Raday, G., & Harris, M. S. (2020) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000727 · Cited by 40
Gender differences in irritable bowel syndrome: the interpersonal connection
Thakur, E. R., Gurtman, M. B., Keefer, L., Brenner, D. M., Lackner, J. M., & Representing the IBS Outcome Study Research Group (2015) · Neurogastroenterology & Motility · doi:10.1111/nmo.12647 · Cited by 21
Camilleri, M. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.20 · Cited by 16
Self-citationPractical Considerations for Recognizing and Managing Severe Irritable Bowel Syndrome
Harris, L. A., & Heitkemper, M. M. (2012) · Gastroenterology Nursing · doi:10.1097/sga.0b013e31823ff0e8 · Cited by 12
Review: Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome
Gaman, A., Bucur, M. C., & Kuo, B. (2009) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x08103656 · Cited by 12
“…the only 5-HT3 antagonist currently FDA approved for the treatment of IBS-D in females for whom it induces significant improvement of GI symptoms such as abdominal pain and discomfort, urgency, stool frequency and consistency at 1 and 12 weeks’ timepoints [Camilleri et al. 2001; Lembo et al. 2001].”
BackgroundAlternating bowel pattern: what do people mean?
CHOUNG, R. S., LOCKE, G. R., ZINSMEISTER, A. R., MELTON, L. J., & TALLEY, N. J. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02953.x · Cited by 5
Metadata
- Authors
- Camilleri, M., Chey, W. Y., Mayer, E. A., Northcutt, A. R., Heath, A., Dukes, G. E., McSorley, D., & Mangel, A. M.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2001-07-23
- Volume
- 161
- Issue
- 14
- Pages
- 1733
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2018343808
- Cited by
- 302
- References
- 8
- FWCI
- 16.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
